XML 42 R26.htm IDEA: XBRL DOCUMENT v3.23.1
SCENDIA PURCHASE AGREEMENT (Tables)
 12 Months Ended
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]  
SCHEDULE OF BUSINESS ACQUISITION, PRO FORMA INFORMATION

 

           
   Year Ended December 31, 
   2022   2021 
Net Revenue  $51,770,977   $30,783,017 
Net Loss  $(7,356,563)  $(8,344,339)
Scendia Biologics LLC [Member]  
Restructuring Cost and Reserve [Line Items]  
SCHEDULE OF PURCHASE CONSIDERATIONS

The total purchase consideration, subject to typical post-closing adjustments, as determined by the Company was as follows:

 

Consideration  Equity Shares   Dollar Value 
Fair value of Sanara common shares issued   291,686   $6,032,066 
Cash consideration        1,562,668 
Fair value of contingent earnout consideration        3,000,000 
Total purchase consideration       $10,594,734 
SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED

 

Description  Amount 
Cash  $201,406 
Net working capital (excluding cash)   1,294,499 
Fixed assets, net   42,300 
Noncontrolling interest in Sanara Biologics, LLC   2,638 
Customer relationships   7,155,000 
Deferred tax liabilities   (1,702,890)
Goodwill   3,601,781 
Net assets acquired  $10,594,734